{"id":"NCT05033080","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","officialTitle":"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (CF) Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-09-14","primaryCompletion":"2023-05-12","completion":"2023-11-21","firstPosted":"2021-09-02","resultsPosted":"2024-06-10","lastUpdate":"2024-10-03"},"enrollment":435,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"VX-121/TEZ/D-IVA","otherNames":["VX-121/VX-661/CTP-656","VX-121/VX-661/VX-561","VX-121/tezacaftor/deutivacaftor"]},{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]},{"type":"DRUG","name":"Placebo (matched to VX-121/TEZ/D-IVA)","otherNames":[]},{"type":"DRUG","name":"Placebo (matched to ELX/TEZ/IVA)","otherNames":[]},{"type":"DRUG","name":"Placebo (matched to IVA)","otherNames":[]}],"arms":[{"label":"ELX/TEZ/IVA","type":"ACTIVE_COMPARATOR"},{"label":"VX-121/TEZ/D-IVA","type":"EXPERIMENTAL"}],"summary":"The purpose of this study evaluates the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who were heterozygous for F508del and a minimal function mutation (F/MF participants).","primaryOutcome":{"measure":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","timeFrame":"From Baseline Through Week 24","effectByArm":[{"arm":"ELX/TEZ/IVA","deltaMin":0.3,"sd":null},{"arm":"VX-121/TEZ/D-IVA","deltaMin":0.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":139,"countries":["United States","Australia","Czechia","Germany","Hungary","Ireland","Israel","New Zealand","Portugal","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["39756424","37983082"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":202},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","COVID-19","Cough","Nasopharyngitis","Headache"]}}